Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ
226.75
+2.81 (+1.25%)
Closed
Oct 7, 2026
Day's Range
222.96230.13
52 wk Range
197.81495.55
Financial Statements - ALNY - Alnylam Pharmaceuticals, Inc.
Revenue
3.71B▲ 65.2%
Net Income
313.74M▲ 212.8%Net Margin 8.4%
EBITDA
676.21M▲ 13477.2%
Free Cash Flow
465.38M▲ 1192.7%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 3.71B | 2.24B | 1.82B | 1.03B | 844.28M | 492.85M |
| Cost of Goods | 681.87M | 323.37M | 310.40M | 168.81M | 140.14M | 78.05M |
| Gross Profit | 3.03B | 1.92B | 1.51B | 868.60M | 704.14M | 414.80M |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 501.57M | -176.88M | -282.17M | -785.07M | -708.65M | -828.43M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -37.26M | -180.62M | -125.68M | -210.76M | -2.05M | 45.52M |
| Pre Tax Income | 323.15M | -377.37M | -433.51M | -1.12B | -852.14M | -855.60M |
| Income Tax | 9.40M | -99.21M | 6.72M | 4.16M | 680K | 2.68M |
| Net Income | 313.74M | -278.15M | -440.24M | -1.13B | -852.82M | -858.28M |
| EPS Basic | 2.39 | -2.18 | -3.52 | -9.3 | -7.2 | -7.46 |
| EPS Diluted | 2.33 | -2.18 | -3.52 | -9.3 | -7.2 | -7.46 |
| Basic Shares Outstanding | 131M | 127.65M | 124.90M | 121.68M | 118.45M | 114.98M |
| Diluted Shares Outstanding | 131M | 127.65M | 124.90M | 121.68M | 118.45M | 114.98M |
| Ebit | 575.77M | -235.51M | -312.29M | -971.02M | -709.12M | -771.10M |
| Ebitda | 676.21M | -5.05M | -107.32M | -680.91M | -636.69M | -733.52M |
| Net Income Continuous Operations | 313.74M | -278.15M | -440.24M | -1.13B | -852.82M | -858.28M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
